



Intended Use

Quantitative determination of Kappa Light Chain (KAP) in human serum by turbidimetric immunoassay.

For professional in vitro diagnostic use only.

Diagnostics Implications

The determination of Kappa/lambda in human serum is important for the diagnosis and subtyping of monoclonal gammopathies.

Whereas polyclonal immunoglobulins (normal or enhanced concentration) exhibit both Kappa and lambda types of light chains in a roughly constant ratio of 2:1, monoclonal immunoglobulins exhibit only one type of light chain. Increased production of monoclonal immunoglobulins or free monoclonal light chains leads to a Kappa/lambda quotient outside the reference range indicating the existence of a monoclonal gammopathy.

Method

Measurement of antigen-antibody reaction by the end-point method.

Reagents Provided

The same reagents are supplied in different volume formats depending on the I.S.E. S.r.I. analysers utilised and installed reagent support.

Supplied Volumes

| oupplied volulles | | |
|-------------------|--------------|---------------|
| | Product Code | |
| | R3330000045 | A-R1100003701 |
| Vial size | 18 / 18 mL | 50 / 20 mL |
| Reagent 1 | 1 x 16.8 mL | 1x 50.0 mL |
| Reagent 2 | 1x 4.0 mL | 1x 9.0 mL |

Reagent format

| Reagent | Format | Code |
|--------------------------------|--------------|--------|
| Reagent 1 – Buffer (liquid) | Ready to Use | 149C03 |
| Reagent 2 – Antiserum (liquid) | Ready to Use | 149C02 |

Reagent Contents

| Reagent 1: | Conc. | U.M. |
|--|----------|------|
| Phosphate buffered saline | - | - |
| Enhancer | - | - |
| Sodium azide | 0.95 | g/L |
| Reagent 2: | | |
| Phosphate buffered saline | - | - |
| Polyclonal goat anti-human Kappa Light | Variable | - |
| Chain | | |
| Sodium azide | 0.95 | g/L |

Stability and Storage

The reagents are stable until expiry date when kept at 2-8°C. Stability in the instrument is at least 4 weeks if contamination is avoided. Do not freeze.

Reagents required but not supplied

- 1. Saline (9 g/L NaCl)
- 2. Calibrators and Controls

| Key Reference | Description |
|---------------|-------------------------------|
| R1300002501 | Protein Calibrator High, 1 mL |
| R1400000901 | Immunology Control Low, 1 mL |
| R1400001001 | Immunology Control High, 1 mL |

Pooled human serum, liquid and stabilized. Contains 0.95 g/L sodium azide. Values are stated in the insert.

Sample collection and storage

Use fresh serum. If the test cannot be carried out on the same day, the serum may be stored at 2-8°C for 48 hours. If stored for a longer period, the sample should be frozen.

General Assay Procedure

Application sheets are available upon request for use with I.S.E. S.r.l. automated systems. All applications not explicitly approved by I.S.E. S.r.l. cannot be guaranteed in terms of performance and must therefore be established by the operator. Wavelength λ =340nm.

Sample/Control/Standard: dilute 1:2 in saline 9 g/L.

Reference curve: generate a reference curve by diluting the standard high level Ref. R1300002501 1:1, 1:2, 1:4, 1:8, 1:16 in saline 9 g/L. Use saline

9 g/L as zero point.

Quality control

It is necessary, each time the kit is used, to perform the quality controls and to check that values obtained are within the acceptance range provided in the insert. Each laboratory

should establish its own mean and standard deviation and adopt a quality control program to monitor laboratory testing.

If erratic results occur, please contact an authorised ISE representative.

Normal Ranges

200-440 mg/dL (IFCC).

Reference values are considered indicative since each laboratory should establish reference ranges for its own patient population. The analytical results should be evaluated with other information coming from patient's clinical history.

Performances

The performance characteristics for the Kappa Light Chain reagents were measured on a clinical chemistry analyzer.

Measuring range: 0 - 800 mg/dL
Detection Limit: 40 mg/dL
Hookeffect: No risk

Sensitivity: 0.0005 ABS units/concentration unit

Precision of the method

| Trecision of the method | | | | | | |
|-------------------------|------|------|--------|------|--|--|
| Condition | U.M. | Low | Medium | High | | |
| Intra-Run | CV% | 3.55 | 2.83 | 2.03 | | |
| Inter-Run | CV% | | 2.65 | 3.72 | | |

Accuracy of the method

| Control | U.M. | Assigned | Measured |
|-----------|-------|-----------------|----------|
| Bio-Rad 1 | mg/dL | 233 (186 - 280) | 251 |
| Bio-Rad 2 | mg/dL | 711 (569 - 853) | 696 |

Specificity: Monospecific.

Interferences: No interference for: Hemoglobin (1000 mg/dL), Bilirubin

(20 mg/dL), Turbidity (5%).

Limitations: None

Comparison with Nephelometry: y = 0.8998 x+44.745 r = 0.9923

Stability at 2 - 8°C: at least 3 years after production

Precautions and Warnings

- 1. In vitro diagnostic use only.
- Refer to the safety data sheets (SDS) and take the necessary precautions for the use of laboratory reagents.
- 3. Do not use after expiry date and do not interchange reagents from different lots.
- 4. Replace caps on reagents immediately after use. Do not switch caps.
- Do not pipet by mouth. Do not smoke, eat, drink or use cosmetics during the use of the reagent. Do not swallow.
- Sodium azide has been reported to form lead or copper azide in laboratory plumbing which may explode on percussion. Flush drains whit water thoroughly after disposing of fluids containing sodium azide.
- 7. Polyethylene glycol is non biohazardous.
- 8. Each donor unit used in the preparation of the reagents, standards and controls was found to be negative for the presence of HIV1 and HIV2 antibodies, as well as for the hepatitis B surface antigen and anti-hepatitis C antibodies, using a method approved by the FDA. However, the material must be considered potentially hazardous and handled with the same care as samples taken from patients.
- Cuts, abrasions, and other skin lesions should be properly protected with an appropriate waterproof dressing.
- Take care to avoid self-inoculation, splashing of mucous membranes or generation
 of aerosols. Laboratory gloves should be worn while handling patients' samples or
 disposing of solid or liquid wastes.
- 11. In addition to the eventual risk indications regarding the active components, the reagents contain inactive components such as preservatives (e.g. sodium azide or others) and detergents. The total concentrations of these components are lower than the limits reported by the current directive sand following modification and amendments. However, it is recommended to handle reagents carefully, to avoid ingestion and contact with eyes, skin and mucus membranes and to use laboratory reagents according to good laboratory practice.
- All human samples must be handled and disposed of as potentially infectious materials.

Disposal of reagent

Disposal of reagents must be performed in accordance with the EC regulations regarding waste, or the local national or regional legislation.

Reporting of serious incidents

The user must report (through the distributor) any serious accident occurring in relation to the device to both the manufacturer and the competent authority of the European Union Member State in which the user and / or patient is established. For other jurisdictions,

| ISE s.r.l. | 7 | | Kappa Light Chain | | Instr | uction For Use | (6 | 5-11-22 | |
|---|---|-----|-------------------|------------------------|----------------------|----------------|----|---------|--------|
| | Ш | DEE | R3330000045 | R1 : 1x 16.8 mL | R2 : 1x 4.0 r | nL | | | .D - 1 |
| CUSTOMISED SOLUTIONS FOR YOUR LABORATORY | | REF | A-R1100003701 | R1: 1x 50.0 mL | R2 : 1x 9.0 r | nL | | IVD | Rev |

reports of serious incidents must be produced in accordance with regulatory

Symbols on labels and packaging

| | abels and packaging | |
|-------------|------------------------------------|--|
| IVD | In vitro diagnostic medical device | |
| REF | Catalog Number | |
| LOT | Lot number | |
| *** | Manufacturer | |
| Σ | Expiry date | |
| 1 | Temperature limitation | |
| Ţ i | Consult Instructions for use | |
| Rn | Reagent "n" | |

- 1. Lievens, M. M., J. Clin. Chem. Clin. Biochem. <u>27</u>, 519-523 (1989) 2. Boege, F. et al., Lab. Med. <u>13</u>, 369-374 (1989) 3. Dati, F. et al., Lab. Med. <u>13</u>, 87-90 (1989)

| Revision | history | |
|----------|------------|--------------------------|
| Rev.D | 15-11-2022 | Revision of the document |